FDA CDER Portes O&M SAS Drug Development Software Maintenance

The U.S. Food and Drug Administration intends to award a contract for operations and maintenance support of the Portes system to Executive Information Systems (EIS), 6901 Rockledge Drive, Suite 600, Bethesda, MD 20827. Portes uses COTS software to create an environment where authorized users and software tools can access application studies after they have been processed by the SAS Drug Development (SDD) software. The software tools interface with Portes via an Application Programming Interface built into the SDD COTS product. The Portes system is implemented within the FDA's Information System Architecture (ISA) as evidenced by the Authority to Operate (ATO) designation that was granted by the FDA in 2014. In order to fully support Portes operational and maintenance needs, the FDA requires application support in the test/pre-production/production environments; upgrade existing SDD from the current version of 3.5 to the most up to date version 4.x to comply with FDA IT standards for server infrastructure; and, SDD software maintenance. EIS's GSA Federal Supply Schedule includes the required professional services to support the application support and upgrade; however, EIS's FSS does not include the SDD software maintenance. EIS is the only SAS authorized GSA FSS reseller to the US Government of SAS professional services performed by SAS personnel based on an exclusive arrangement for resale on Government schedule contracts. For administrative convenience, the FDA intends to add the SDD software maintenance to the resultant EIS Federal Supply Schedule order in accordance with the procedures set forth in 8.402(f). The Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1. Interested entities may identify their interest and capability to respond to the requirement or submit quotation no later than 5pm Eastern Time on Wednesday, April 27th. This notice is not a request for quotation. Any vendor that believes it can provide the above stated requirements can provide supporting documents demonstrating their capability and specifications statement. The FDA will review all responses received; however, the Government retains the sole discretion not to further compete the proposed acquisition based on responses to this notice. Information can be sent to Danielle Pena at Danielle.Pena@fda.hhs.gov. No telephone requests will be accepted.